Media stories about AMAG Pharmaceuticals (NASDAQ:AMAG) have trended somewhat positive on Tuesday, according to Accern Sentiment. The research group ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. AMAG Pharmaceuticals earned a coverage optimism score of 0.21 on Accern’s scale. Accern also gave media stories about the specialty pharmaceutical company an impact score of 45.5748511902168 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the news articles that may have effected Accern Sentiment’s analysis:
- AMAG Pharmaceuticals, Inc. (AMAG) Now Covered by Analysts at Morgan Stanley (americanbankingnews.com)
- Shining the Spotlight on AMAG Pharmaceuticals Inc (AMAG)’s Numbers: Technicals At a Glance – Financial News Review (finnewsreview.com)
- AMAG Pharmaceuticals Appoints Laura Williams, MD as Senior Vice President of Clinical Development – GlobeNewswire (press release) (globenewswire.com)
- Insider Activity for Investors: First Horizon National Corporation (FHN) (wisdomsave.com)
- AMAG Pharmaceuticals Appoints Laura Williams, M.D. as Senior Vice President of Clinical Development (finance.yahoo.com)
AMAG has been the topic of a number of recent analyst reports. Zacks Investment Research raised shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $22.00 price target on the stock in a research report on Tuesday, July 11th. ValuEngine raised shares of AMAG Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday, July 25th. Deutsche Bank AG reissued a “hold” rating and set a $24.00 price target on shares of AMAG Pharmaceuticals in a research report on Thursday, August 31st. Morgan Stanley initiated coverage on shares of AMAG Pharmaceuticals in a research report on Friday. They set an “overweight” rating and a $26.00 price target on the stock. Finally, Cantor Fitzgerald restated a “hold” rating on shares of AMAG Pharmaceuticals in a report on Monday, July 24th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $27.92.
AMAG Pharmaceuticals (NASDAQ:AMAG) opened at 20.00 on Tuesday. The company has a 50-day moving average of $18.09 and a 200-day moving average of $19.94. AMAG Pharmaceuticals has a 52 week low of $16.00 and a 52 week high of $36.83. The company’s market cap is $705.76 million.
AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.58) by $0.18. AMAG Pharmaceuticals had a negative return on equity of 4.81% and a negative net margin of 7.58%. The business had revenue of $158.39 million for the quarter, compared to analyst estimates of $158.83 million. During the same quarter in the previous year, the firm earned $1.45 earnings per share. The company’s revenue was up 24.3% on a year-over-year basis. On average, equities analysts expect that AMAG Pharmaceuticals will post ($1.38) EPS for the current year.
In other news, SVP Julie Krop sold 4,938 shares of the business’s stock in a transaction dated Thursday, July 13th. The stock was sold at an average price of $20.00, for a total transaction of $98,760.00. Following the sale, the senior vice president now owns 28,336 shares in the company, valued at $566,720. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 3.80% of the stock is currently owned by insiders.
WARNING: “AMAG Pharmaceuticals (AMAG) Given Media Impact Score of 0.21” was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at https://sportsperspectives.com/2017/09/12/amag-pharmaceuticals-amag-given-media-impact-score-of-0-21.html.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.